{"nctId":"NCT01404312","briefTitle":"Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)","startDateStruct":{"date":"2012-05-23","type":"ACTUAL"},"conditions":["Tuberculosis","HIV Infections"],"count":3000,"armGroups":[{"label":"RPT plus INH Regimen (Arm A)","type":"EXPERIMENTAL","interventionNames":["Drug: Rifapentine (RPT)","Drug: Isoniazid (INH)","Dietary Supplement: Pyridoxine (Vitamin B6)"]},{"label":"INH Regimen (Arm B)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Isoniazid (INH)","Dietary Supplement: Pyridoxine (Vitamin B6)"]}],"interventions":[{"name":"Rifapentine (RPT)","otherNames":[]},{"name":"Isoniazid (INH)","otherNames":[]},{"name":"Pyridoxine (Vitamin B6)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV-1 infection\n* Tuberculin skin test (TST) reactivity greater than or equal to 5 mm or a positive interferon gamma release assay (IGRA) at any time prior to study entry, OR living in a high TB burden area. More information on this criterion can be found in the protocol.\n* Laboratory values obtained within 30 days prior to study entry:\n\n  1. Absolute neutrophil count (ANC) greater than 750 cells/mm\\^3\n  2. Hemoglobin greater than or equal to 7.4 g/dL\n  3. Platelet count greater than or equal to 50,000/mm\\^3\n  4. AST (SGOT) and ALT (SGPT) less than or equal to three times the upper limit of normal (ULN)\n  5. Total bilirubin less than or equal to 2.5 times the ULN\n* Chest radiograph or chest CT scan without evidence of active tuberculosis, unless one has been performed within 30 days prior to entry\n* Female participants of reproductive potential must have a negative serum or urine pregnancy test performed within 7 days prior to study entry. More information on this criterion can be found in the protocol.\n* All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization) while receiving RPT and for 6 weeks after stopping this drug\n* Female participants who are participating in sexual activity that could lead to pregnancy must agree to use one reliable non-hormonal form of contraceptive while receiving RPT and for 6 weeks after stopping this drug. More information on this criterion can be found in the protocol.\n* Weight of greater than or equal to 30 kg\n* Participant or legal guardian is able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Treatment for active or latent TB (pulmonary or extrapulmonary) within 2 years prior to study entry or, at screening, presence of any confirmed or probable TB based on criteria listed in the current ACTG Diagnosis Appendix\n* History of multi-drug resistant (MDR) or extensively-drug resistant (XDR) TB at any time prior to study entry\n* Known exposure to MDR or XDR TB (e.g., household member of a person with MDR or XDR TB) at any time prior to study entry\n* Treatment for more than 14 consecutive days with a rifamycin or more than 30 consecutive days with INH at any time during the 2 years prior to enrollment\n* For participants taking antiretroviral therapy (ART) at study entry, only approved nucleoside reverse transcriptase inhibitors (NRTIs) with efavirenz (EFV) or nevirapine (NVP) for at least 4 weeks were permitted\n* History of liver cirrhosis at any time prior to study entry.\n* Evidence of acute hepatitis, such as abdominal pain, jaundice, dark urine, and/or light stools within 90 days prior to study entry\n* Diagnosis of porphyria at any time prior to study entry\n* Peripheral neuropathy greater than or equal to Grade 2 according to the December 2004 (Clarification, August 2009) Division of AIDS (DAIDS) Toxicity Table, within 90 days prior to study entry\n* Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation\n* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements\n* Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry\n* Breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"13 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown Cause","description":"Incidence rate (events per 100 person-years) was estimated, and 95.1% confidence interval used to account for interim analysis of primary efficacy outcome.","paramType":"NUMBER","dispersionType":"95.1% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6506","spread":null},{"groupId":"OG001","value":"0.6736","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Occurrence of One or More Serious Adverse Events (SAEs) Versus no SAEs","description":"Occurrence of any SAE that meets the ICH definition of an SAE","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1405","spread":null},{"groupId":"OG001","value":"1390","spread":null}]},{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"108","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Targeted Adverse Event","description":"Targeted adverse events include each new grade 3 or 4 laboratory value or sign or symptom that is at least one grade increase from baseline for the following: nausea and vomiting; cutaneous; drug-associated fever; elevated aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]), alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]), or bilirubin; and peripheral neuropathy","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1445","spread":null},{"groupId":"OG001","value":"1446","spread":null}]},{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Each Category of Ordered Categorical Variable Indicating Most Stringent Level of Study Drug Management Due to Toxicity That Was Required Over the Treatment Period","description":"Ordered categories include:\n\n1. Premature permanent treatment discontinuation\n2. Treatment hold for more than 7 consecutive days\n3. None of the above","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"25","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"31","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1461","spread":null},{"groupId":"OG001","value":"1442","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Death From Any Cause","description":"Data table estimates for percentage who died by each time point were estimated using Kaplan-Meier at 1, 2, 3, and 4 years post-entry.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":null},{"groupId":"OG001","value":"0.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":null},{"groupId":"OG001","value":"1.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null},{"groupId":"OG001","value":"1.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":null},{"groupId":"OG001","value":"2.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Incidence of Death Due to a Non-TB Event","description":"Cumulative incidence function estimated nonparametrically, treating TB-related deaths as competing risks.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Antibiotic Resistance Among Mycobacterium Tuberculosis (MTB) Isolates in Participants Who Develop Active Tuberculosis","description":"Among MTB-diagnosed participants who underwent drug-susceptibility testing, the number who had any resistance to a particular drug.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Efavirenz (EFV) Plasma Concentrations in Arm A","description":"Mean and standard deviation.\n\nWeek 16 samples have not yet been analyzed because the metabolite assay is being validated, and requires submission for approval by the Clinical Pharmacology Quality Assurance Program. Analysis of week 16 samples are anticipated to be available in September 2019.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3787","spread":"4922"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3870","spread":"7011"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4082","spread":"4916"}]}]},{"categories":[]}]},{"type":"SECONDARY","title":"Nevirapine (NVP) Plasma Concentrations in Arm A","description":"Mean and standard deviation","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7573","spread":"3789"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6234","spread":"4283"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5797","spread":"3963"}]}]}]},{"type":"SECONDARY","title":"EFV Plasma Concentrations in Arm B","description":"For Version 2.0 of the protocol only, measured in the first 90 participants randomized to Arm B who enter the study taking EFV and who meet dose timing criteria.\n\nOutcome measure was not assessed because no participants enrolled under version 2.0 of the protocol were on Efavirenz at study entry.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":1496},"commonTop":["Cough","Blood sodium decreased","Pyrexia","Oropharyngeal pain","Neutrophil count decreased"]}}}